Recent Quotes (30 days)

You have no recent quotes
chg | %

argenx NV - ADR  

(Public, NASDAQ:ARGX)   Watch this stock  
Find more results for ARGX
-0.26 (-0.29%)
Apr 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 87.93 - 89.66
52 week 17.33 - 90.20
Open 88.00
Vol / Avg. 172,998.00/128,457.00
Mkt cap 2.87B
P/E     -
Div/yield     -
EPS     -
Shares 32.17M
Beta     -
Inst. own     -
May 9, 2018
Q1 2018 argenx NV Earnings Call Add to calendar
May 9, 2018
Q1 2018 argenx NV Earnings Release Add to calendar
May 8, 2018
argenx NV Annual Shareholders Meeting Add to calendar
Apr 24, 2018
argenx SE - Special Call - 4:00PM EDT - Add to calendar
Apr 18, 2018
argenx NV at Kempen & Co Life Sciences Conference
Mar 13, 2018
argenx NV at Cowen Health care Conference
Mar 1, 2018
Q4 2017 argenx NV Earnings Call - Webcast
Mar 1, 2018
Full Year 2017 argenx NV Earnings Release & Q4 Business Update
Feb 1, 2018
argenx NV at Degroof Petercam Healthcare Seminar
More events from DailyFinance »    


Willemstraat 5
BREDA, 4811 AH
+31-76-3030488 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


argenx NV, formerly arGEN X BV is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Officers and directors

Peter Verhaeghe Chairman of the Supervisory Board
Bio & Compensation  - Reuters
Tim Van Hauwermeiren MBA Chief Executive Officer
Bio & Compensation  - Reuters
Eric Castaldi Chief Financial Officer
Bio & Compensation  - Reuters
Hans de Haard Chief Scientific Officer
Bio & Compensation  - Reuters
Debbie Allen Ph.D. Senior Director, Business Development
Bio & Compensation  - Reuters
Torsten Dreier Chief Development Officer
Bio & Compensation  - Reuters
Jacobus Rasser IP Counsel
Bio & Compensation  - Reuters
Michael Saunders Senior Director Targets & Programs
Bio & Compensation  - Reuters
Alain Thibault Chief Medical Officer
Bio & Compensation  - Reuters
John de Koning Member of the Supervisory Board
Bio & Compensation  - Reuters